DreamCIS, Inc.

Equities

A223250

KR7223250002

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
2,725 ^KRW	+2.06%		-5.22%	-16.28%

Feb. 22	Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay	CI
2023	T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	CI

DreamCIS, Inc. has completed an IPO in the amount of KRW 20.186311 billion.

May 21, 2020 at 12:00 am EDT

DreamCIS, Inc. has completed an IPO in the amount of KRW 20.186311 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,354,786 PriceRange: KRW 14900 Discount Per Security: KRW 596

Latest news about DreamCIS, Inc.

Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay	Feb. 22	CI
T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	Dec. 21	CI
T&R Biofab Co., Ltd. announced that it expects to receive KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	Dec. 13	CI
DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding	22-03-27	CI
DreamCIS, Inc. announced that it expects to receive KRW 2.9999925 billion in funding	22-03-16	CI
DreamCIS, Inc. has completed an IPO in the amount of KRW 20.186311 billion.	20-05-21	CI
DreamCIS, Inc. has filed an IPO.	19-09-27	CI
Hangzhou Tigermed Consulting Co., Ltd. completed the acquisition of 98.14% stake in DreamCIS, Inc. from Leenos Corp. and Won-Young Choi.	15-09-21	CI
Hangzhou Tigermed Consulting Co., Ltd. signed letter of intent to acquire 70% stake in DreamCIS, Inc. from Leenos Corp. for KRW 27 billion.	15-06-07	CI
Leenos Corp. completed the acquisition of 70% stake in DreamCIS Inc. from Choi Won-Jung.	14-03-26	CI
Leenos Corp. signed an external valuation contract to acquire 70% stake in DreamCIS Inc. from Choi Won-Jung for KRW 13.1 billion.	14-01-16	CI

Chart DreamCIS, Inc.

Duration

Period

More charts

Company Profile

DreamCIS Inc is a Korea-based company principally engaged in the business of contract clinical trial. The Company mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The Company provides its services within domestic market and to overseas markets.

Sector

Healthcare Facilities & Services

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DREAMCIS, INC.	-16.28%	45.64M
SONIC HEALTHCARE LIMITED	-18.11%	8.02B
RADNET, INC.	+36.93%	3.51B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-26.72%	2.97B
SYNLAB AG	-7.88%	2.48B
DR. LAL PATHLABS LIMITED	-14.30%	2.23B
NEOGENOMICS, INC.	-15.20%	1.76B
FLEURY S.A.	-22.23%	1.44B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.19%	1.25B
ADICON HOLDINGS LIMITED	-11.20%	1.11B

Medical & Diagnostic Laboratories